drug · antibody
obinutuzumab
Marketedupdated 5mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 20 investigational indications.
indications
investigational
Lupus
targets
B-lymphocyte antigen CD20
all catalysts(14)
approval · 14
Nov 1, 2013
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jun 27, 2014
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Dec 24, 2014
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Sep 23, 2015
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Feb 26, 2016
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 16, 2017
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 16, 2017
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Mar 27, 2020
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Feb 14, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jul 12, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jul 27, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Oct 17, 2025
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Oct 17, 2025
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Dec 17, 2025
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Trials studying obinutuzumab
- phase3A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- phase3A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- phase2A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- phase1A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- —Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- phase3A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- phase2TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
News(2)
- Unlocking cell surface protein research with site-specific labelingApplications in flow cytometry, cell sorting, target validation, and therapeutic discoverybiospace · 16d ago
- Beeline flies into phase 3 as oral lupus drug soars past placeboA phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.fiercebiotech · 21d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that